Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.
about
The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairmentMeta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic CriteriaApolipoprotein A-I: insights from redox proteomics for its role in neurodegenerationUpdate on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics.The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging.Plasma alkaline phosphatase is elevated in Alzheimer's disease and inversely correlates with cognitive function.Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease.Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's diseaseGenome-wide association study of prolactin levels in blood plasma and cerebrospinal fluidAdditions to the Human Plasma Proteome via a Tandem MARS Depletion iTRAQ-Based Workflow.Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins.Combined analysis of the glia secretome and the CSF proteome: neuroinflammation and novel biomarkers.Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes.Inflammatory mediators as biomarkers in brain disorders.Strategy to reduce free radical species in Alzheimer's disease: an update of selected antioxidants.Role of Vital Trace Elements in Nanocurcumin-Centered Formulation: A Novel Approach to Resuscitate the Immune System.MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models.Metabolomic-guided discovery of Alzheimer's disease biomarkers from body fluid.Structure-selective anisotropy assay for amyloid Beta oligomers.CSF Biomarkers for Alzheimer's Disease Diagnosis.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Detection of a Peptide Biomarker by Engineered Yeast Receptors.Super-Resolution Microscopy of Cerebrospinal Fluid Biomarkers as a Tool for Alzheimer's Disease Diagnostics.Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer's disease patients.The Amyloid-β Peptide in Amyloid Formation Processes: Interactions with Blood Proteins and Naturally Occurring Metal IonsCurrently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer’s Disease and Mild Cognitive Impairment
P2860
Q26827320-BC27696F-944F-42B7-9DF0-A8F97652A2F7Q26864063-1DA88888-4AB1-4219-9993-C084878229ABQ27026686-C027031C-B421-404A-890D-C66EF8F6E3C9Q30845482-5CD27832-F7C5-485F-AF4B-9B11BEAA6AACQ33912803-3B210144-6E28-4EB0-AF7A-E57073A52BCAQ34296479-93925F27-E089-42CA-8AD5-087BC01B979FQ35031967-BE1A5CBC-2B2D-4E79-88DF-E5F4FA0BE99AQ35034130-7CC76541-C6BD-40CD-986E-CE3F2977BEB3Q35284971-72447A7D-E221-4AB6-86F5-9087B07D0300Q36064238-5BB88336-B23A-49E0-AD8D-1DD0FE69A34AQ36664014-CCE4B458-AF7A-43F2-8F27-8AA9B4008BE7Q37105161-10D46626-7843-46EB-9E9E-B2EC12987BE1Q37727199-01D79A10-A578-4290-AE10-0E8E1D1A5E7FQ38125769-1B607E7D-4E76-424C-A899-939F1092CC23Q38167639-4C1D7E93-843D-45AF-BC6A-63DF97A1652CQ38253060-CA1A8C52-0662-4780-9D33-D007EC8EBD37Q38691852-250FA5CA-D452-4693-AD83-49AC7555D5D0Q38729312-9916F634-4837-4076-B7CB-96C8D70A33C8Q39181900-71FDAA71-D3DA-4C0E-89E0-D7F04E1FACD9Q41738061-25A62AC5-4E9B-4697-931F-91BA28637D50Q41897818-8FF5013E-CF3E-4801-B57A-C7224A01EA9EQ47587631-7E11AEA0-3E01-4F4C-BDB4-A13092E70BBAQ48173200-40154195-47D9-4F2D-884B-817A61582DCEQ48226326-2C40317B-FFB1-42B3-99A2-F988462E6FCAQ48622733-99B450BB-A932-47AA-B845-9239E8B57756Q58486506-A31B9569-55C3-42AE-9251-2BE8BB5ED26EQ59052213-F0613310-5D82-48C6-8140-BA96E5B9EAE6
P2860
Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Peptides and proteins in plasm ...... ficacy of Alzheimer's disease.
@en
Peptides and proteins in plasm ...... ficacy of Alzheimer's disease.
@nl
type
label
Peptides and proteins in plasm ...... ficacy of Alzheimer's disease.
@en
Peptides and proteins in plasm ...... ficacy of Alzheimer's disease.
@nl
prefLabel
Peptides and proteins in plasm ...... ficacy of Alzheimer's disease.
@en
Peptides and proteins in plasm ...... ficacy of Alzheimer's disease.
@nl
P2860
P921
P1476
Peptides and proteins in plasm ...... ficacy of Alzheimer's disease.
@en
P2093
Christopher D Aluise
Renã A Sowell
P2860
P304
P356
10.1016/J.BBADIS.2008.07.008
P407
P577
2008-08-07T00:00:00Z